A review of quality of life in Alzheimer's disease: Part 2: Issues in assessing drug effects

PharmacoEconomics

Volumn 14, Issue 6, 1998, Pages 613-627

  Salek, Sam S ^a   Walker, Melvyn D ^a   Bayer, Antony J ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARNITINE DERIVATIVE; DONEPEZIL; FATTY ACID DERIVATIVE; GINKGO BILOBA EXTRACT; LEVOCECARNINE; SR 3; TACRINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CLINICAL TRIAL; DEMENTIA; HUMAN; METHODOLOGY; PRIORITY JOURNAL; PSYCHOMETRY; QUALITY OF LIFE; RATING SCALE; RELIABILITY; REVIEW; TREATMENT OUTCOME; VALIDATION PROCESS;

ALZHEIMER DISEASE; CLINICAL TRIALS; HUMANS; QUALITY OF LIFE;

EID: 0032440071     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199814060-00003     Document Type: Review

References (42)

1. Parnetti L, Senin U, Mecocci P. Cognitive enhancement therapy for Alzheimer's disease: the way forward. Drugs 1997; 53: 752-68
2. Borson S, Raskind MA. Clinical features and pharmacologic treatment of behavioural symptoms of Alzheimer's disease. Neurology 1997; 48 Suppl. 6: S17-24
3. Gottfries CG. Review of treatment strategies. Acta Neurol Scand Suppl 1992; 139: 63-8
4. Takman A. Nonpharmacologic treatment of behavioural symptoms. Acta Neurol Scand Suppl 1992; 139: 81-3
5. Hollister L, Gruber N. Drug treatment of Alzheimer's disease: effects on caregiver burden and patient quality of life. Drugs Aging 1996; 8: 47-55
6. Williams M, Davis RE. Alzheimer's disease and related dementias: prospects for treatment. Exp Opin Invest Drugs 1997; 6: 735-57
7. Smyth KA. Social management of Alzheimer's disease. Clin Geriatr Med 1994; 10 (2): 367-78
8. Hepler CD, Strand L. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm 1990; 47: 533-43
9. Whitehouse PJ. Pharmacoeconomics of dementia. Alzheimer Dis Assoc Disord 1997; 11 Suppl. 5: S22-33
10. Walker MD, Salek SS, Bayer AJ. A review of quality of life in Alzheimer's disease. Part 1: issues in assessing disease impact. Pharmacoeconomics 1998; 14 (5): 499-530
11. Schneider LS, Olin JT. Overview of clinical trials of hydergine in dementia. Arch Neurol 1994; 51: 787-98
12. Howard K, Rockwood K. Quality of life in Alzheimer's disease. Dementia 1995; 6: 113-6
13. Sano M, Bell K, Cote L, et al. Double-blind parallel design pilot study of acetyl levocarnitine in patients with Alzheimer's disease. Arch Neurol 1992; 49: 1137-41
14. Bergner M, Bobbitt RA, Carter WB, et al. The sickness impact profile: development and final revision of a health status measure. Med Care 1981; 19: 787-805
15. Squire LR, Wetzel CD, Slater PC. Memory complaint after electroconvulsive therapy: assessment with a new self-rating instrument. Biol Psychiatry 1979; 14: 791-801
16. Sarao MV, Ricci C, Peri G, et al. Valutazione del livello di autonomia nelle demenze. Psich Med 1987; 3: 44-6
17. Bottini G, Vallar G, Cappa S, et al. Oxiracetam in dementia: a double-blind, placebo-controlled study. Acta Neurol Scand 1992; 86: 237-41
18. Guinot P, Wesnes K. A quality of life scale for the elderly: validation by factor analysis. IRCS Med Sci 1985; 13: 965
19. Wesnes K, Simmons D, Rook M, et al. A double-blind placebo-controlled trial of Tanakan in the treatment of idiopathic cognitive impairment in the elderly. Hum Psychopharmacol 1987; 2: 159-69
20. Blau TH. Quality of life, social indicators and criteria of change. Prof Psychol 1977; 8: 464-73
21. Rogers SL, Friedhoff LT, Apter JT, et al. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia 1996; 7: 293-303
22. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998; 50: 136-45
23. Yehuda S, Rabinovtz S, Carasso RL, et al. Essential fatty acids preparation (SR-3) improves Alzheimer's patients quality of life. Int J Neurosci 1996; 87: 141-9
24. Bergner M, Bobbitt RA, Kressel S, et al. The sickness impact profile: conceptual formulation and methodology for the development of a health status measure. Int J Health Serv 1976; 6: 393-415
25. Dejong R, Osterlund OW, Roy GW. Measurement of quality of life changes in patients with Alzheimer's disease. Clin Ther 1989; 11: 545-54
26. Davis KL, Thal LJ, Gamzu ER, et al. A double-blind, placebo-controlled multicenter study of Tacrine for Alzheimer's disease. N Engl J Med 1992; 327: 1253-9
27. Farlow M, Gracon SI, Hershey LA, et al. A controlled trial of tacrine in Alzheimer's disease. JAMA 1992; 268: 2523-9
28. Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994; 271: 985-91
29. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969; 9: 176-86
30. McDowell I, Newell C. Measuring health: a guide to rating scales and questionnaires. New York: Oxford University Press, 1987
31. Wilcock GK, Surmon DJ, Scott M, et al. An evaluation of the efficacy and safety of tetrahydroaminoacridine (THA) without lecithin in the treatment of Alzheimer's disease. Age Ageing 1993; 22: 316-24
32. Thal LJ, Schwanz G, Sano M, et al. A multicenter double-blind study of controlled-release physosligmine for the treatment of symptoms secondary to Alzheimer's disease. Neurology 1996; 47: 1389-95
33. Gerety MB, Cornell JE, Mulrow CD, et al. The Sickness Impact Profile for Nursing Homes (SIP-NH). J Gerontol 1994; 49: M2-8
34. Busschbach JJ, Brouwer WB, van der Donk A. An outline for a cost-effectiveness analysis of a drug for patients with Alzheimer's disease. Pharmacoeconomics 1998; 13: 21-24
35. Kinney J, Stephens MAP. Caregiver Hassles Scale: assessing the daily hassles of caring for a family member with dementia. Gerontologist 1989; 29: 328-32
36. Teri L, Truax P, Logsdon R, et al. Assessment of behavioural problems in dementia: the Revised Memory and Behavior Problems Checklist. Psychol Aging 1992; 7: 622-31
37. Zarit SH, Reever KE, Bach-Peterson J. Relatives of the impaired elderly: correlates of feelings of burden. Gerontologist 1980; 20: 649-55
38. Teri L, Borson S, Kiyak HA, et al. Behavioral disturbance, cognitive dysfunction, and functional skill: prevalence and relationship in Alzheimer's disease. J Am Geriatr Soc 1989; 37: 109-16
39. Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. MD State Med J 1965; 14: 61-5
40. Patterson MB, Mack JL, Neundorfer MM, et al. Assessment of functional ability in Alzheimer's disease: a review and a preliminary report on the Cleveland Scale for Activities of Daily Living. Alzheimer Dis Assoc Disord 1992; 6: 145-63
41. Spiegel R, Brunner C, Ermini-Funfschilling D, et al. A new-behavioral assessment scale for geriatric out- and inpatients: the NOSGER (Nurses' Observational Scale for Geriatric Patients). J Am Geriatr Soc 1991; 39: 339-47
42. Juniper EF, Guyatt GH, Jaeschke R. How to develop and validate a new health-related quality of life instrument. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia (PA): Lippincott-Raven Publishers. 1996: 49-56